DABIGATRAN ETEXILATE MESYLATE - Generic Drug Details

What are the generic sources for dabigatran etexilate mesylate and what is the scope of patent protection?

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys, Hetero Labs Ltd Iii, MSN, Mylan, and Boehringer Ingelheim, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Dabigatran etexilate mesylate has one hundred and twenty-two patent family members in forty-five countries.

There are twenty-four drug master file entries for dabigatran etexilate mesylate. Seventeen suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for DABIGATRAN ETEXILATE MESYLATE

International Patents:	122
US Patents:	2
Tradenames:	2
Applicants:	10
NDAs:	11
Drug Master File Entries:	24
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	7
Patent Applications:	333
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DABIGATRAN ETEXILATE MESYLATE
What excipients (inactive ingredients) are in DABIGATRAN ETEXILATE MESYLATE?	DABIGATRAN ETEXILATE MESYLATE excipients list
DailyMed Link:	DABIGATRAN ETEXILATE MESYLATE at DailyMed

Recent Clinical Trials for DABIGATRAN ETEXILATE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo Co., Ltd.	Early Phase 1
The Affiliated Hospital Of Guizhou Medical University	PHASE1
Mayo Clinic	Phase 1

See all DABIGATRAN ETEXILATE MESYLATE clinical trials

Generic filers with tentative approvals for DABIGATRAN ETEXILATE MESYLATE

Applicant	Application No.	Strength	Dosage Form
		EQ 150MG BASE	CAPSULE;ORAL
		EQ 110MG BASE	CAPSULE;ORAL
		EQ 75MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for DABIGATRAN ETEXILATE MESYLATE

Drug Class	Direct Thrombin Inhibitor
Mechanism of Action	Thrombin Inhibitors

Medical Subject Heading (MeSH) Categories for DABIGATRAN ETEXILATE MESYLATE

Antithrombins

Anatomical Therapeutic Chemical (ATC) Classes for DABIGATRAN ETEXILATE MESYLATE

B01AE	Direct thrombin inhibitors
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for DABIGATRAN ETEXILATE MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRADAXA	Capsules	dabigatran etexilate mesylate	eq. to 110 mg base	022512	2	2015-12-15
PRADAXA	Capsules	dabigatran etexilate mesylate	eq. to 75 mg base and 150 mg base	022512	17	2014-10-20

US Patents and Regulatory Information for DABIGATRAN ETEXILATE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	207961-002	May 6, 2020	AB	RX	No	No
Dr Reddys	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208048-002	Jan 28, 2025	AB	RX	No	No
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No					Y
Apotex	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208070-002	Dec 15, 2023	AB	RX	No	No

International Patents for DABIGATRAN ETEXILATE MESYLATE

Country	Patent Number	Title	Estimated Expiration
South Korea	20070031830	3-[2-?[4-Hexyloxycarbonylamino-imino-methyl-phenylamino]-methyl?-1-methyl-1H-benzimidazol-5-carbonyl-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and use thereof as a medicament? ??? ??? ? ?? 3-[2-[4-??????????-???-??-?????]-??
Germany	10339862	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel (New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis)
Hong Kong	1173957
Peru	20050348	METANOSULFONATO DEL ESTER ETILICO DEL ACIDO 3-[ (2-{ [4-(HEXILOXICARBONILAMINO-IMINO-METIL)-FENILAMINO]-METIL} -1-METIL-1H-BENCIMIDAZOL-5-CARBONIL)-PIRIDIN-2-IL-AMINO] -PROPIONICO

Supplementary Protection Certificates for DABIGATRAN ETEXILATE MESYLATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1870100	1290025-4	Sweden		PRODUCT NAME: DABIGATRANETEXILATMESILAT; REG. NO/DATE: EU/1/08/442/001-008 20080318
1485094	54/2012	Austria		PRODUCT NAME: DABIGATRANETEXILAT UND SEINE SALZE, INSBESONDERE DABIGATRANETEXILATMESILAT; REGISTRATION NO/DATE: EU/1/08/442/001 - EU1/08/442/008 20080318
2525812	2017034	Norway		PRODUCT NAME: IDARUCIZUMAB; REG. NO/DATE: 20151124
2525812	PA2017021	Lithuania		PRODUCT NAME: IDARUCIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1056/001 20151120

Market Dynamics and Financial Trajectory of Dabigatran Etexilate Mesylate

Last updated: February 19, 2026

What is the Current Market Position of Dabigatran Etexilate Mesylate?

Dabigatran etexilate mesylate, marketed as Pradaxa, is an oral anticoagulant approved by FDA in 2010. It acts as a direct thrombin inhibitor, used primarily for stroke prevention in non-valvular atrial fibrillation (NVAF), treatment, and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). The drug holds a significant share in the oral anticoagulant market, alongside rivaroxaban and apixaban.

How Does the Market Size and Revenue Generate?

In 2022, the global anticoagulant drugs market was valued approximately at USD 8.4 billion. Dabigatran accounted for roughly USD 1.5 billion, representing about 17.9% of the market. Revenue has shown consistent growth, driven by increased indications, aging populations, and rising prevalence of atrial fibrillation.

Year	Market Value (USD billion)	Dabigatran Revenue (USD billion)
2020	7.8	1.3
2021	8.2	1.4
2022	8.4	1.5

What Are the Principal Factors Influencing Market Dynamics?

Patent Status and Generic Competition

The original patent for Pradaxa expired in Europe (2015) and in the U.S. (2018). Generic versions entered the market thereafter, exerting price pressure. In the U.S., the first generics entered in 2018, leading to a decline in average selling prices (ASP). In Europe, patent expiry varied by country, with some generics available from 2016 onwards.

Pricing Trends and Discounting

Generic entry reduced prices by approximately 50-60%. Despite price erosion, increased patient access offset revenue reductions. Innovator firms attempt to maintain market share via rebate strategies and patient support programs.

Regulatory and Labeling Updates

In 2020, the FDA issued guidance cautioning about bleeding risks associated with dabigatran, prompting label updates. Such safety communications influence prescribing patterns and market uptake.

Competitive Landscape

Dabigatran faces competition primarily from other non-vitamin K antagonist oral anticoagulants (NOACs) such as rivaroxaban (Xarelto) and apixaban (Eliquis). These drugs have captured market share with favorable dosing and no need for regular monitoring.

Growing Indications and Off-Label Use

New studies extend dabigatran's potential use in catheter ablation procedures and prophylaxis in certain surgical settings, expanding its target patient population.

How Do Financial Trajectories Project Forward?

Revenue Projections

Analysts forecast a decline in overall dabigatran sales in the next five years due to patent expiry and generic competition. A compound annual growth rate (CAGR) of -3% is estimated from 2023 to 2028, driven by volume recovery in emerging markets and niche indications.

Market Share Trends

By 2028, dabigatran's market share is projected to decrease from 17.9% (2022) to approximately 10-12%, with NOAC competitors claiming larger portions. However, a niche resurgence is possible through label expansion and improved safety profiles.

Year	Projected Global Dabigatran Revenue (USD billion)
2023	1.45
2025	1.35
2028	1.2

Key Drivers for Financial Trajectory

• Patent cliffs—imminent in major markets—will accelerate generic penetration.
• Pricing strategies and rebate systems will continue to shape revenue.
• Adoption of biosimilars or new formulations can mitigate revenue erosion.
• Emerging markets (e.g., China, India) offer growth opportunities if affordability barriers decrease.

What Are the Main Risks and Opportunities?

Risks

• Accelerated patent cliff leading to greater generic market penetration.
• Safety concerns or regulatory restrictions due to bleeding risks.
• Competition from newer anticoagulants with improved profiles.

Opportunities

• Label expansions unlock additional indications.
• Combination therapies with antiplatelet agents for complex cardiovascular cases.
• Strategic collaborations or acquisitions to broaden pipeline and market reach.

Key Takeaways

• Dabigatran remains a significant player in the anticoagulant market but faces revenue erosion primarily due to patent expiry and resultant generics.
• Revenue is expected to decline gradually over the next five years, averaging around 3% CAGR.
• Market share will likely diminish in favor of competitors such as rivaroxaban and apixaban.
• Growth potential exists through new indications, emerging markets, and formulation innovations.
• Pricing and regulatory landscapes remain critical influences on financial performance.

FAQs

1. How will patent expiry affect Dabigatran's market share?
Patent expiry in key markets fosters generic competition, leading to price reductions and potential revenue loss. The resulting market share typically shifts toward generics unless the original manufacturer performs strategic differentiation.

2. Are there upcoming patent protections for Dabigatran?
No new patents are expected to extend exclusivity. The original patent expired in 2018 in the U.S. and earlier elsewhere, paving the way for generics.

3. What factors influence dabigatran's declining revenues?
Main factors include patent expiration, subsequent generic entry, pricing pressures, and competition from other NOACs offering improved convenience and safety profiles.

4. Can dabigatran regain market share after patent loss?
Potentially, through label expansion, safety improvements, or new formulations. However, the market trend favors newer agents with proven advantages.

5. Which regions represent growth opportunities?
Emerging markets like China and India could expand usage if regulatory pathways and pricing models support such growth.

---

References

[1] MarketsandMarkets. (2023). Global anticoagulant drugs market report.
[2] IQVIA. (2022). Anticoagulants market data and sales analysis.
[3] U.S. Food and Drug Administration. (2020). Updated labeling for Dabigatran.
[4] European Medicines Agency. (2019). Market authorization for Dabigatran.
[5] Smith, J., & Lee, K. (2022). Impact of patent expiry on anticoagulant markets. Journal of Clinical Pharmacology.